AZN vs EBS · P/E 28, $288.38B cap vs rev $1.04B
AstraZeneca PLC (AZN) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
AstraZeneca PLC (AZN) is a drug manufacturers - general company listed on US.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
AZN does not have a complete income-statement cache yet.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
AZN currently screens at market cap $288.38B and trailing P/E 28.0. EBS currently screens at market cap $416.4M.
Not investment advice. Open the AZN and EBS stock pages for the full models.
Not investment advice.